| Nathan John Young, DPM | |
|
222 Walnut Ave Sw, Roanoke, VA 24016-4723 | |
| (540) 344-3668 | |
| (540) 343-2457 |
| Full Name | Nathan John Young |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 15 Years |
| Location | 222 Walnut Ave Sw, Roanoke, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841425600 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 0103301073 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Amedisys Home Health Care | Roanoke, VA | Home health agency |
| Lewisgale Medical Center | Salem, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Foot And Ankle Specialists Of The Mid-atlantic Llc | 6305017633 | 147 |
News Archive
UNC School of Medicine researchers have developed a new laboratory model of the infection- and inflammation-plagued airways of cystic fibrosis (CF) patients.
VIVUS, Inc. today announced that the company filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for QNEXA® (phentermine/topiramate) Controlled Release Capsules in the European Union (EU). The proposed indication in the EU is for the treatment of obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a mildly hypocaloric diet.
Eczema is not just kids' stuff. Although the skin disease is commonly diagnosed in infancy and early childhood, it also can affect adults - sometimes more profoundly than younger patients.
TetraLogic Pharmaceuticals announced today that the Company has completed dosing of the first cohort in a Phase 1 clinical trial of its selective SMAC mimetic, TL32711. The Phase 1 trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies. The study will also assess the pharmacokinetics, pharmacodynamics and anti-tumor activity of TL32711.
› Verified 5 days ago
| Provider Name | Foot And Ankle Associates Of Southwest Virginia Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1841220530 PECOS PAC ID: 8527070796 Enrollment ID: O20060707000259 |
News Archive
UNC School of Medicine researchers have developed a new laboratory model of the infection- and inflammation-plagued airways of cystic fibrosis (CF) patients.
VIVUS, Inc. today announced that the company filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for QNEXA® (phentermine/topiramate) Controlled Release Capsules in the European Union (EU). The proposed indication in the EU is for the treatment of obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a mildly hypocaloric diet.
Eczema is not just kids' stuff. Although the skin disease is commonly diagnosed in infancy and early childhood, it also can affect adults - sometimes more profoundly than younger patients.
TetraLogic Pharmaceuticals announced today that the Company has completed dosing of the first cohort in a Phase 1 clinical trial of its selective SMAC mimetic, TL32711. The Phase 1 trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies. The study will also assess the pharmacokinetics, pharmacodynamics and anti-tumor activity of TL32711.
› Verified 5 days ago
| Provider Name | Foot And Ankle Specialists Of The Mid-atlantic Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1073804712 PECOS PAC ID: 6305017633 Enrollment ID: O20170424001337 |
News Archive
UNC School of Medicine researchers have developed a new laboratory model of the infection- and inflammation-plagued airways of cystic fibrosis (CF) patients.
VIVUS, Inc. today announced that the company filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for QNEXA® (phentermine/topiramate) Controlled Release Capsules in the European Union (EU). The proposed indication in the EU is for the treatment of obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a mildly hypocaloric diet.
Eczema is not just kids' stuff. Although the skin disease is commonly diagnosed in infancy and early childhood, it also can affect adults - sometimes more profoundly than younger patients.
TetraLogic Pharmaceuticals announced today that the Company has completed dosing of the first cohort in a Phase 1 clinical trial of its selective SMAC mimetic, TL32711. The Phase 1 trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies. The study will also assess the pharmacokinetics, pharmacodynamics and anti-tumor activity of TL32711.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nathan John Young, DPM 222 Walnut Ave Sw, Roanoke, VA 24016-4723 Ph: (540) 344-3668 | Nathan John Young, DPM 222 Walnut Ave Sw, Roanoke, VA 24016-4723 Ph: (540) 344-3668 |
News Archive
UNC School of Medicine researchers have developed a new laboratory model of the infection- and inflammation-plagued airways of cystic fibrosis (CF) patients.
VIVUS, Inc. today announced that the company filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for QNEXA® (phentermine/topiramate) Controlled Release Capsules in the European Union (EU). The proposed indication in the EU is for the treatment of obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a mildly hypocaloric diet.
Eczema is not just kids' stuff. Although the skin disease is commonly diagnosed in infancy and early childhood, it also can affect adults - sometimes more profoundly than younger patients.
TetraLogic Pharmaceuticals announced today that the Company has completed dosing of the first cohort in a Phase 1 clinical trial of its selective SMAC mimetic, TL32711. The Phase 1 trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies. The study will also assess the pharmacokinetics, pharmacodynamics and anti-tumor activity of TL32711.
› Verified 5 days ago
Shenandoah Valley Podiatry Associates, Ltd. Podiatrist Medicare: Medicare Enrolled Practice Location: 60 Summerfield Ct, Suite 102, Roanoke, VA 24019 Phone: 540-904-1458 Fax: 855-495-0994 | |
Mr. David Lamont Nielson, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 222 Walnut Ave Sw, Roanoke, VA 24016 Phone: 540-344-3668 Fax: 540-769-6381 | |
Wesley Maurice Leong, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1906 Belleview Ave Se, Roanoke, VA 24014 Phone: 540-981-7000 | |
Dr. Peter F Kelly, D.P.M. Podiatrist Medicare: May Accept Medicare Assignments Practice Location: 4106 Electric Rd, Roanoke, VA 24014 Phone: 540-989-3338 Fax: 540-989-5425 | |
Dr. Craig Alan Wilhelms, DPM, PC Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 3 Riverside Cir, Roanoke, VA 24016 Phone: 540-510-6200 Fax: 540-857-5306 | |
Jennifer Anne Keller, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 60 Summerfield Ct, Suite 102, Roanoke, VA 24019 Phone: 540-904-1458 Fax: 855-495-0994 | |
Dr. Marc A. Platt, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 3 Riverside Cir, Roanoke, VA 24016 Phone: 540-725-1226 Fax: 540-857-5306 |